The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers - PubMed (original) (raw)
. 2002 Jul 15;62(14):4048-53.
Affiliations
- PMID: 12124340
The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers
Yasuhiro Tada et al. Cancer Res. 2002.
Abstract
Mechanisms for bladder carcinogenesis and the development of recurrentbladder cancer remain unclear. Aberrant methylation of the 5' CpG island is thought to play an important role in the inactivation of the tumor suppressor genes in cancer. To study whether specific or bulk hypermethylation predicts intrabladder recurrence, we determined the frequency of aberrant promoter hypermethylation of seven genes, hMLH1, O(6)-methylguanine-DNA-methyltransferase (MGMT), p16, Von Hippel-Lindau (VHL), death-associated protein kinase (DAP-kinase), glutathione S-transferase P1 (GST-P1) and E-cadherin in 55 superficial bladder cancers and 5 normal urothelial epithelia by methylation-specific PCR (MSP). These patients of superficial bladder cancer had been followed prospectively by cystoscopy. Simultaneous hypermethylation of three genes or more among the seven genes was observed in 2 (7%) of 30 patients in the nonrecurrence group and 7 (28%) of 25 patients in the recurrence group. There was a significant concordance between the number of methylated genes and the development of recurrence (P = 0.012). In particular, the recurrence rate for 24 months was 88% for hypermethylation of DAP-kinase and 28% for nonmethylation of DAP-kinase. Hypermethylation of DAP-kinase is, therefore, a strong indicator of the superficial bladder cancer associated with a high recurrence rate (P < 0.001; hazards ratio, 7.01). Our results suggest that hypermethylation of DAP-kinase might be a useful prognostic marker for disease recurrence in superficial bladder cancers.
Similar articles
- Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.
Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. Kwong J, et al. Clin Cancer Res. 2002 Jan;8(1):131-7. Clin Cancer Res. 2002. PMID: 11801549 - Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D. Rosas SL, et al. Cancer Res. 2001 Feb 1;61(3):939-42. Cancer Res. 2001. PMID: 11221887 - Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT, Lee SH, Sung SW, Kim JH. Kim YT, et al. Ann Thorac Surg. 2005 Apr;79(4):1180-8; discussion 1180-8. doi: 10.1016/j.athoracsur.2004.09.060. Ann Thorac Surg. 2005. PMID: 15797047 - [Hypermethylation of DAP-kinase gene CpG Island in malignant lymphoma with B-cell phenotype].
Nakatsuka S, Takakuwa T, Aozasa K. Nakatsuka S, et al. Rinsho Byori. 2001 Dec;49(12):1242-7. Rinsho Byori. 2001. PMID: 11797395 Review. Japanese. - Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract.
Phé V, Cussenot O, Rouprêt M. Phé V, et al. BJU Int. 2009 Oct;104(7):896-901. doi: 10.1111/j.1464-410X.2009.08696.x. Epub 2009 Jun 12. BJU Int. 2009. PMID: 19522860 Review.
Cited by
- Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. Coyne GO', et al. Cancer Chemother Pharmacol. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. Cancer Chemother Pharmacol. 2020. PMID: 32314030 Free PMC article. Clinical Trial. - DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.
Dai L, Ma C, Zhang Z, Zeng S, Liu A, Tang S, Ren Q, Sun Y, Xu C. Dai L, et al. PLoS One. 2016 Dec 1;11(12):e0167228. doi: 10.1371/journal.pone.0167228. eCollection 2016. PLoS One. 2016. PMID: 27907054 Free PMC article. Review. - Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
Kim YJ, Kim WJ. Kim YJ, et al. Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S77-88. doi: 10.4111/icu.2016.57.S1.S77. Epub 2016 May 25. Investig Clin Urol. 2016. PMID: 27326410 Free PMC article. Review. - The relationship between promoter methylation of p16 gene and bladder cancer risk: a meta-analysis.
Qi D, Li J, Jiang M, Liu C, Hu Y, Li M, Su J, Que B, Ji W. Qi D, et al. Int J Clin Exp Med. 2015 Nov 15;8(11):20701-11. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26884993 Free PMC article. - Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
Zhang X, Zhang Y, Liu X, Fang A, Wang J, Yang Y, Wang L, Du L, Wang C. Zhang X, et al. Oncotarget. 2016 Jan 19;7(3):3255-66. doi: 10.18632/oncotarget.6487. Oncotarget. 2016. PMID: 26657502 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous